Literature DB >> 10623563

Clostridium perfringens beta-toxin forms multimeric transmembrane pores in human endothelial cells.

V Steinthorsdottir1, H Halldórsson, O S Andrésson.   

Abstract

Beta-toxin is one of the lethal toxins of Clostridium perfringens. It shares sequence homology with the pore-forming alpha-toxin of Staphylococcus aureus and structural homology has been indicated by mutagenesis studies. Human endothelial cells are sensitive to the toxic effect of alpha-toxin and in order to investigate the function of beta-toxin we have looked at the effect of the protein on human umbilical vein endothelial cells. We show that like alpha-toxin beta-toxin induces release of arachidonic acid in a dose dependent manner. In addition we show that both toxins cause leakage of inositol from the cells, consistent with the formation of transmembrane pores. The effect of toxin mutants on endothelial cells correlates with the lethal dose of each mutant in mice. Furthermore, we demonstrate the formation of heat stable toxin multimers in the cell membrane. Multimer formation was not observed on other cell types tested. We conclude that beta-toxin is a cell specific pore-forming toxin, structurally and functionally related to alpha-toxin of Staphylococcus aureus. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10623563     DOI: 10.1006/mpat.1999.0323

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  30 in total

1.  Properties of Bacillus cereus hemolysin II: a heptameric transmembrane pore.

Authors:  George Miles; Hagan Bayley; Stephen Cheley
Journal:  Protein Sci       Date:  2002-07       Impact factor: 6.725

Review 2.  Recent progress in understanding the pathogenesis of Clostridium perfringens type C infections.

Authors:  F A Uzal; B A McClane
Journal:  Vet Microbiol       Date:  2011-02-26       Impact factor: 3.293

Review 3.  Role of pore-forming toxins in bacterial infectious diseases.

Authors:  Ferdinand C O Los; Tara M Randis; Raffi V Aroian; Adam J Ratner
Journal:  Microbiol Mol Biol Rev       Date:  2013-06       Impact factor: 11.056

4.  Identification and characterization of Clostridium perfringens beta toxin variants with differing trypsin sensitivity and in vitro cytotoxicity activity.

Authors:  James R Theoret; Francisco A Uzal; Bruce A McClane
Journal:  Infect Immun       Date:  2015-02-02       Impact factor: 3.441

5.  Clostridium perfringens beta-toxin forms potential-dependent, cation-selective channels in lipid bilayers.

Authors:  O Shatursky; R Bayles; M Rogers; B H Jost; J G Songer; R K Tweten
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

6.  Synergistic effects of Clostridium perfringens enterotoxin and beta toxin in rabbit small intestinal loops.

Authors:  Menglin Ma; Abhijit Gurjar; James R Theoret; Jorge P Garcia; Juliann Beingesser; John C Freedman; Derek J Fisher; Bruce A McClane; Francisco A Uzal
Journal:  Infect Immun       Date:  2014-04-28       Impact factor: 3.441

Review 7.  Botulinum toxins--cause of botulism and systemic diseases?

Authors:  H Böhnel; F Gessler
Journal:  Vet Res Commun       Date:  2005-05       Impact factor: 2.459

8.  Clostridium perfringens iota toxin: characterization of the cell-associated iota b complex.

Authors:  Bradley G Stiles; Martha L Hale; Jean Christophe Marvaud; Michel R Popoff
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

9.  Effects of Clostridium perfringens beta-toxin on the rabbit small intestine and colon.

Authors:  Jorge E Vidal; Bruce A McClane; Juliann Saputo; Jaquelyn Parker; Francisco A Uzal
Journal:  Infect Immun       Date:  2008-07-14       Impact factor: 3.441

10.  The p38 MAPK and JNK pathways protect host cells against Clostridium perfringens beta-toxin.

Authors:  Masahiro Nagahama; Masahiro Shibutani; Soshi Seike; Mami Yonezaki; Teruhisa Takagishi; Masataka Oda; Keiko Kobayashi; Jun Sakurai
Journal:  Infect Immun       Date:  2013-07-22       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.